HOYA Posts Record Q2 Profits as MiYOSMART iQ Rollout Accelerates on Back of Landmark Clinical Data
Global optical giant reports 27% jump in operating profit, with second-generation myopia management lens demonstrating zero average progression in 12-month trial.
HOYA Corporation has announced record-breaking second-quarter results for its 2026 financial year, driven by a robust recovery in Life Care profit margins and the surging global demand for its advanced myopia management portfolio.
For eyecare professionals and optical dispensers, the standout takeaway from the FY26 Q2 earnings presentation, released on October 30, is the rapid global rollout of the second-generation MiYOSMART iQ lens, backed by newly published 12-month clinical trial data showing an average of *zero* myopia progression in young patients.
Record Financial Performance
HOYA reported consolidated revenue of ¥260.2 billion for the quarter (July - September 2026), representing an 11% year-on-year increase. More impressively for practice owners and stakeholders watching the supply chain, Operating Profit surged 27% to ¥89.4 billion.
The Life Care Business, which houses HOYA’s eyecare and medical divisions, generated ¥153.4 billion in revenue. Crucially, the division's Operating Profit Margin improved to 21.2%, returning to the company's target range thanks to product mix optimisation and cost efficiencies.
MiYOSMART iQ: A Game-Changer for Myopia Management
The eyeglass lenses segment grew 8% year-on-year, heavily buoyed by value-added products. While HOYA noted that U.S. sales were broadly flat due to ongoing business restructuring, the company’s myopia management (MM) franchise continues to be a massive growth engine, now representing close to 10% of total eyeglass lens sales globally.
HOYA provided a deep dive into the global rollout of MiYOSMART iQ, the second-generation iteration of its flagship Defocus Incorporated Multiple Segments (DIMS) spectacle lens. Following its initial launch in China in late 2025, the lens is expanding rapidly, with HOYA targeting distribution in 54 countries by the end of Q3 FY26.
The clinical evidence supporting the Gen 2 lens is highly compelling for optometrists prescribing myopia management. HOYA presented 12-month results from a randomised controlled trial of 202 myopic children aged 4 to 12.
While children wearing single-vision lenses saw an average myopia progression of -0.534 D, those wearing the first-generation MiYOSMART progressed by -0.255 D. Remarkably, children wearing the new MiYOSMART iQ showed an average progression of just 0.046 D, effectively demonstrating zero average myopia progression over the 12-month period.
The iQ design enhances the myopic defocus signal by positioning defocus areas closer to the lens centre, increasing the defocus power from +3.5D to +4.5D, and expanding the coverage area to accommodate larger frames.
A Billion-Dollar Market Opportunity
HOYA’s presentation highlighted the immense commercial runway remaining in the myopia sector. The company estimates the global myopia management market opportunity at US$3.6 billion (post-affordability adjustment). The MM spectacle lens wholesale market alone is projected to sustain low-to-mid-teens growth, reaching US$1.0 billion by 2030.
With myopia prevalence among children and adolescents currently estimated at 35.8% globally, HOYA stated its intention to leverage the new clinical evidence to outgrow the broader market expansion rate, a strategy that will likely see aggressive marketing support for Australian practices stocking the iQ lens in the coming months.
Contact Lenses and Premium IOLs
In the contact lens division (operating under the eyecity brand), revenue remained broadly flat against a high prior-year base, with a modest 1% growth. HOYA noted that private-label and subscription models are successfully improving customer retention.
In the intraocular lens (IOL) segment, sales grew 5% year-on-year. Despite headwinds in China and reimbursement changes in Germany, HOYA’s premium portfolio specifically its trifocal and enhanced monofocal IOLs, including the Vivinex multiSert platform continued to expand globally. The company reiterated its goal to restore growth in Europe while aggressively expanding advanced technology IOL (ATIOL) sales worldwide.
What This Means for Practices
For B2B eyecare stakeholders, HOYA’s Q2 results signal a strong, stable partner in the optical supply chain. The company's renewed focus on high-margin, clinically validated products like MiYOSMART iQ and premium IOLs provides local optometrists and dispensing opticians with highly effective, evidence-based tools to capture the growing myopia management and cataract surgery markets.
As HOYA accelerates the iQ rollout across the Asia-Pacific region over the next quarter, Australian practices can expect increased availability and potential educational support to help integrate the next-generation DIMS technology into their myopia management protocols.